---
schema_version: "secwatch.filing_event.v1"
accession: "0001790340-24-000078"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:01:32.487295+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immuneering Q3 net loss $14.6M; positive initial Phase 2a data for IMM-1-104

## Summary
- Net loss $14.6M ($0.49/share) vs $12.6M ($0.43) in Q3 2023; cash $50.7M.
- Positive initial Phase 2a data: complete and partial responses with IMM-1-104 + chemo in first-line pancreatic cancer.
- FDA granted Orphan Drug and Fast Track designations for IMM-1-104 in pancreatic cancer.
- Cash runway into Q4 2025; R&D expenses $11.3M, G&A $4.0M.
- Initial data from additional Phase 2a arm and Phase 1 data for IMM-6-415 expected by year end.

## SEC filing metadata
- accession: 0001790340-24-000078
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000179034024000078/0001790340-24-000078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000179034024000078/imrx-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001790340-24-000078
- JSON: https://secwatch.observer/filing/0001790340-24-000078.json
- Plain text: https://secwatch.observer/filing/0001790340-24-000078.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.